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Abstract
Ghrelin, an orexigenic 28 amino-acid peptide, has been studied primarily in relation to the control
of appetite and fat metabolism. In addition to these well-known functions, ghrelin, and its target
receptors, growth hormone secretagogue receptors (GHS-Rs), have been localized to neutrophils,
lymphocytes and macrophages suggesting that ghrelin may be involved in immune modulation. To
assess the therapeutic role of ghrelin in production of pro-inflammatory and anti-inflammatory
cytokines, the effects of exogenous ghrelin administration on the regulation of cytokine release in
lipopolysaccharide (LPS)-activated murine RAW 264.7 macrophages were analyzed. Ghrelin and
GHS-Rs are expressed in murine macrophages. In addition, exogenous ghrelin inhibited the
production of pro-inflammatory cytokines IL-1β & TNF-α in LPS-stimulated murine macrophages
in a dose dependent and time-dependent fashion. Exogenous ghrelin pretreatment resulted in a
decrease in LPS-induced NFκB activation and was presumably the reason for this ghrelin-mediated
effect. In contrast to these findings, exogenous ghrelin significantly augmented the release of the
anti-inflammatory cytokine IL-10 in a dose dependent and time-dependent fashion from LPS-
stimulated murine macrophages. Ghrelin administration enhanced activation of p38 MAPK, which
is known to control the release of IL-10 in macrophages independent of the NFκB pathway. These
effects of ghrelin on both pro- and anti-inflammatory cytokines were offset when a specific GHS-R
receptor antagonist was added to the culture media. In conclusion, these data suggest that ghrelin has
potent anti-inflammatory properties through modulation of secretion of both pro- and anti-
inflammatory cytokines from LPS-stimulated macrophages through distinct signaling cascades.
Therapeutic utility of ghrelin to control, modulate or treat pathologic inflammatory conditions like
endotoxemic shock and ulcerative colitis requires further investigation.
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INTRODUCTION
Ghrelin is a 28 amino acid acylated peptide, which is produced and secreted principally by the
X/A-like enteroendocrine cells of the stomach 1,2. Ghrelin causes robust stimulation of growth
hormone secretion via a G protein-coupled growth hormone secretagogue receptor (GHS-R)
3. Two GHS receptors subtypes, GHS-R1a & GHS-R1b have been identified 3. The GHS-R
type 1a receptor mediates ghrelin’s effects on growth hormone secretion 3. GHR-R 1b still
lacks any known function 3. It is theorized that additional functional GHS-Rs may exist which
mediate ghrelin’s non-endocrine activities, but these putative receptors have not yet been
identified or characterized 4,5,6.
Initial interest in ghrelin has focused on its appetite-stimulant effects. It is currently the only
known circulating orexigenic agent that antagonizes the leptin-induced decrease in food intake
through activation of the hypothalamic neuropeptide Y-Y1 pathway 1,2. Further investigation
revealed that ghrelin has diverse biologic functions in vivo and in vitro, which extend beyond
its effects on the central nervous system 1,2. For example, ghrelin increases cell proliferation
and inhibits apoptosis in vitro including enterocytes 7-11. Ghrelin is now known to have a wide
spectrum of effects on the endocrine, reproductive, and cardiovascular systems, and it is
expected that additional functions of this potent hormone will be identified given the wide
distribution of GHS-Rs throughout a variety of tissues and cell types 1,2.
Recently, new evidence has pointed toward the potential role of ghrelin in influencing the
immune system. This observation includes both in vitro and in vivo data that indicate that
ghrelin receptors are present in leukocytes, some leukocytes endogenously produce ghrelin
(e.g., T cells and human peripheral blood mononuclear cells), and the exogenous administration
of ghrelin may ameliorate pathologic inflammatory conditions 12-20.
The mechanism by which ghrelin ameliorates the inflammatory response has been studied
partially. Initial studies suggest that ghrelin may affect not only the pro-inflammatory Th1
responses but also the Th2 anti-inflammatory response through augmented release of
IL-10.14,20,30 Li et al have shown that ghrelin inhibits activation of NFκB in umbilical
endothelial cells to reduce the production of pro-inflammatory cytokines, a well-known
transcription factor to govern the production of many pro-inflammatory cytokines during
inflammatory insult.20 In addition, ghrelin also induces the production of anti-inflammatory
cytokine such as IL-10 in murine model of colitis. Nevertheless, much further study in this
area is warranted to improve our understanding of the actions of ghrelin in lymphoid tissues.
14 One potential mechanism could be recruitment of p38 MAPK by ghrelin, which is a well-
known signaling entity that controls the production of IL-10 in macrophages through the
transcription factor, Sp1.30
The current study was designed to examine the effects of exogenous ghrelin on LPS-induced
release of pro-inflammatory and anti-inflammatory cytokines in murine macrophages in
vitro and to characterize the signaling mechanisms. Our results both indicate a potent and
beneficial effect of exogenous ghrelin in inflammation and identifies possible mechanisms
through which previous findings13-19 could be better explained. The data in aggregate
suggests a therapeutic role for ghrelin in a variety of clinical conditions in which cytokine
mediated pathology is central.
MATERIALS AND METHODS
Reagents and chemicals
Rat ghrelin, which has same peptide sequence as of endogenous mouse ghrelin, and the GHS-
R antagonist, D[lys-3]-GHRP-6, were purchased from AnaSpec, San Jose, CA. The specific
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chemical inhibitors of NFκB (6-Amino-4-(4-phenoxyphenylethylamino)quinazoline) and p38
MAPK (SB202190) were purchased from Calbiochem, San Diego, CA. The remaining
chemicals required for the studies described were purchased from Sigma Aldrich, St. Louis,
MO unless specified.
Cell Culture System
RAW 264.7 cells obtained from American Type Culture Collection (Manassas, VA) were
maintained in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum (FBS). These
murine macrophages were grown at 37°C in a humidified incubator in 5% CO2 and 95% air.
The RAW 264.7 cells were sub-cultured before confluence and seeded at a density of 5×104
cells/ml for the studies described below.
Western Blot Analyses
To obtain cell lysates for Western blot analyses, cells were harvested and rinsed twice with
phosphate buffered saline (PBS), pH 7.4. The cells were then lysed with a lysis buffer
containing 20mM Tris, pH 7.5, 0.1% Triton X, 0.5% deoxycholate, 1mM
phenylmethylsulfonyl fluoride, 10μg/ml aprotinin, and 10μg/ml leupeptin followed by
centrifugation at 12000g at 4°C. For nuclear proteins, cells were resuspended in hypotonic
buffer on ice, detergent was added to 0.5%, nuclei were pelleted, then suspended in nuclear
protein extract buffer [50 mmol/L HEPES (pH 7.8), 300 mmol/L NaCl, 50 mmol/L KCl, 0.1
mmol/L EDTA, 10% (v/v) glycerol] on ice for 30 min, and spun with the supernatant saved.
The pellet was resuspended in lysis buffer with 1% detergent, sonicated on ice, and pelleted;
the supernatant contained membrane proteins. Total protein concentration was measured in the
resultant extracts using the BCA assay kit according to the manufacturer’s instructions (Sigma,
St Louis, MO) with bovine serum albumin as a standard. Cell extracts containing 30μg total
protein were subjected to SDS/PAGE, and the resolved proteins transferred electrophoretically
to PVDF membranes (Invitrogen, Carlsbad, CA). After blocking with PBS containing 0.2%
casein for 1 h at room temperature, membranes were incubated with primary antibodies in PBS
containing 0.1% Tween 20 overnight at 4°C. After incubation with the secondary antibody,
Vecstain™ ABC kit and DAB liquid substrate were used for chromogenic detection according
to the manufacturer’s instructions.
The primary antibodies used were polyclonal, goat, anti-ghrelin (sc-10368; Santa Cruz
Biotechnolgy, Santa Cruz, CA) and rabbit anti-GHS-R antibodies (sc-20748; Santa Cruz
Biotechnolgy, Santa Cruz, CA). Other antibodies used were monoclonal mouse anti- NFκB
p65, p-p38 MAPK and p38 MAPK (Santa Cruz Biotechnolgy, Santa Cruz, CA). Ghrelin and
cell lysates from rat stomach were used as positive controls, and cell lysate from rat cerebral
cortex was used as a negative control in blots for detection of ghrelin at the protein level.
Similarly, cell lysates from rat hypothalamus/pituitary gland and cerebral cortex were used as
positive and negative controls, respectively, for GHS-R.
Immunoflorescence
For the localization of the GHS-R and ghrelin in subcelluar compartments, RAW 264.7 cells
were tagged with ghrelin and GHS-R antibodies and were enhanced with FITC-labeled
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Briefly, RAW 264.7 cells
were grown in chamber slides to 70% confluence, washed with PBS, fixed with acetone for 5
min and blocked with 1x Casein solution for 20 min. Primary antibodies raised against ghrelin
and GHS-R were applied for an hour at a dilution of 1:400 dissolved in PBS. FITC-labeled
secondary antibodies were applied for 30 min. Finally, the cells were stained by Hoechst 33342
for 10 min to localize nuclei as reference point. For the negative controls, the primary antibodies
were excluded from the staining procedure described above. The slides were analyzed by
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fluorescence microscopy. For immuno-staining of nuclear p65 subunit of the NFκB, the exact
same procedure was used after various treatments as described in the figure legend.
Cell Viability Assay
Cell viabilty was quantified by 3-(4, 5-dimethylthiazolyl-2yl)-2, 5-diphenyltetrazolium (MTT)
assay. Cells were seeded into 96-well plates at a density of 5×105 cells per well and were serum
“starved” overnight before any peptide treatment. Cells were treated with lipopolysaccharide
(LPS) (0-1μg/ml) in the presence or absence of n-octonylated ghrelin (AnaSpec, San Jose, CA)
dissolved in PBS at concentrations ranging from 0 to 1 μM. After 24 h, the media were aspirated
and cells quantified by MTT assay (Trevigen Inc, Gaithersburg, MD) according to the
manufacturer’s instructions. The plates were read using a Vmax microplate spectrophotometer
(Molecular Devices, Sunnyvale, CA) at a wavelength of 562nm. Each independent experiment
was performed four times.
Measurement of Cytokines by ELISA
The cells were treated with LPS, ghrelin, and GHS-R antagonist (D[lys-3]-GHRP-6) as
required for 0-24 h in 24 well plates. Briefly, RAW264.7 cells were seeded in 24-well plates
at a density of 5×105 cells/ml. The cells were allowed to attach to the bottom of the plates fro
24 h. The cells were “serum-starved” for 12 h before treating with various doses of ghrelin for
4 h. Following the pre-treatment with ghrelin, cells were treated with LPS (1μg/ml) for various
time points ranging from 0-24 h. The supernatants were collected at specific times (0-24 h)
and were stored immediately at -70 °C till the time of analysis. TNF-α and IL-1β ELISA kits
(TiterZyme, An Arbor, MI) and IL-10 ELISA kit (Cell Sciences, Canton, MA) were used to
measure these cytokines according to the manufacturer’s instructions.
Statistical Analyses
All data were expressed as means ± SD for a series of ‘n’ number of the experiments. ANOVA
was utilized followed by Tukey’s post hoc comparisons to determine statistically significant
differences between the groups. A p value of less than 0.05 was considered significant. All of
the statistics were performed using the program Statistica (StatSoft Inc. Tulsa, OK).
RESULTS
RAW264.7 macrophages were incubated for 24 h with LPS at doses ranging from 0 to 1 μg/
ml in the absence or presence of ghrelin (0-1μM). Cell viability and proliferation were not
altered under any of these conditions as assessed using the MTT assay (data not shown).
Subsequent studies were done within this dose range of LPS and ghrelin.
Next, Western blotting demonstrated that both ghrelin and GHS-R were expressed by the
macrophages at the protein level (Figure 1a). Immuno-fluorescence demonstrated that GHS-
R was localized to the cell membrane (Figure1b, Panels D-F), while ghrelin was localized to
the cell membrane and intracellularly (Figure 1b, Panels G-I). This observation indicates that
ghrelin and its receptors are present in the macrophages and is consistent with the hypothesis
that ghrelin can directly affect macrophage function through its receptors and not by some
indirect means.
LPS is known to stimulate release of IL1-β and TNF-α in a dose-dependent fashion in RAW
264.7 cells as demonstrated by others previously 17,18. Pretreatment of macrophages with
exogenous ghrelin at doses ranging from 100 pM to 1 μM for 4h prior to LPS stimulation (1
μg/ml) resulted in a dose-dependent inhibition of both IL1-β and TNF-α production
(Figures 2a and 3a). Furthermore, the time-dependent production of these two cytokines
induced by LPS (1 μg/ml) was down-regulated by pretreatment with ghrelin (100nM)
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(Figure 2b and 3b), however, when the ghrelin pretreatment was carried out in the presence
of the GHS-R antagonist (D [lys-3]-GHRP-6), LPS-induced IL1-β production returned to
levels equivalent to that observed with incubation with LPS alone (Figure 2c). Similarly, when
the ghrelin pretreatment was carried out in the presence of the GHS-R antagonist, LPS-induced
TNF-α production returned to levels nearly equivalent to, but still statistically different from
that observed with incubation with LPS alone (Figure 3c). These results suggest that the effects
of ghrelin pre-treatment on LPS-induced pro-inflammatory cytokine production are mediated
specifically by ghrelin via GHS-R.
Nuclear factor kappa-B (NFκB) is an important transcription factor which controls the
production of various pro-inflammatory cytokines, including TNF-α and IL-1β.21-24 Data
from this study indicate that exogenous ghrelin inhibits the translocation of p65 subunit of
NFκB from the cytosolic region to the nuclear compartment (Fig. 4a & b), which is an integral
component of the NFκB activation. Furthermore, the chemical antagonism of NFκB by 6-
Amino-4-(4-phenoxyphenylethylamino)quinazoline results in the inhibition of p65 subunit
translocation in a manner similar to ghrelin. This observation suggests that exogenous ghrelin
may inhibit the production of TNF-α and IL-1β via effects on NFκB- controlled transcription.
Interleukin 10 (IL-10) is a cytokine that inhibits inflammatory and mediated
responses25-35Our data show that pre-treatment with exogenous ghrelin augmented the
production of IL-10 in LPS- stimulated macrophages in a dose-dependent and time-dependent
manner (Figure 5a and b). The effect of ghrelin pre-treatment was offset when the GHS-R
antagonist (D [lys-3]-GHRP-6) was added to the culture medium (Figure 5c). These findings
indicate that ghrelin specifically enhances the production of the anti-inflammatory system via
a GHS-R in contrast to ghrelin’s inhibitory effect on the pro-inflammatory cytokines.
Finally, we tried to unravel the mechanism, by which ghrelin could augment the IL-10 release
in macrophages. Our Western analysis demonstrated that LPS stimulates the induction of p38
MAPK and that ghrelin pre-treatment enhances the phosphorylation of p38 MAPK (Fig 6).
The antagonism of either GHS-R or p38 MAPK by the specific chemical inhibitor, SB 202190,
resulted in the loss of the enhanced p38 MAPK activity, implying that GHS-R lies upstream
to p38 MAPK and p-p38 MAPK signaling. These findings are consistent with the work of Wei
Ma et al’s, who have shown that IL-10 release is dependent on the p38MAPK pathway and is
independent of NFκB signaling.30
DISCUSSION
Ghrelin is a relatively novel gastric peptide that has been the focus of intense investigation in
recent past due to its role in appetite stimulation. Several additional studies now indicate that
ghrelin affects several other organ systems and has quite diverse and far-reaching effects 1,2.
Ghrelin has mitogenic as well as anti-apoptotic effects on various cell types 7-10,12. Of note,
ghrelin and its target receptors (GHS-Rs) have been localized to human neutrophils,
lymphocytes, and macrophages suggesting that ghrelin may modulate immune cell responses
12,14. Other groups have shown that ghrelin inhibits the production of various pro-
inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-8 in human endothelial cells
13,14,20. Taken together, these data indicate that ghrelin may play an important role in
ameliorating immune cell responses and pathologic inflammatory states.
The aim of the present study was to characterize the role of ghrelin in the production of pro-
inflammatory and anti-inflammatory cytokines in murine macrophages. We confirmed initially
that ghrelin and the receptor through which it mediates its activities, the growth hormone
secretagogue receptor (GHS-R), are both expressed in RAW 264.7 murine macrophages. GHS-
Rs and ghrelin were localized on the plasma membrane. Immuno-fluorescent staining with the
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ghrelin antibody demonstrated positive staining within the cytoplasm. This latter finding may
be due to the fact that the ghrelin antibody used in this study stains for pre-proghrelin as well
ghrelin itself. Hence, these stains may be identifying an immature form of ghrelin within the
cytoplasm. The co-existence of ghrelin and its receptor within murine macrophages indicate
that ghrelin may not only modulate the immune system via an endocrine fashion but also an
autocrine / paracrine fashion. Indeed, De Vriese C et al have shown that ghrelin can act in
autocrine fashion.37 The focus of the current study was, however to analyze the effect of
exogenous ghrelin at therapeutic doses. We theorize that endogenous ghrelin is not produced
in sufficient quantities to neutralize the LPS-induced cytokine production but therapeutic doses
of ghrelin administered exogenously may have significant neutralizing capability. This
assumption, however, does not completely rule out the potential role of endogenously produced
ghrelin in modulation of the macrophage function under other pathologic conditions.
In the next series of experiments, we examined the effect of ghrelin on LPS-induced production
of IL-1β & TNF-α by the murine macrophages. Ghrelin inhibited the release of these pro-
inflammatory cytokines in a dose-dependent and time-dependent fashion through GHS-R. Our
findings are consistent with recently published results of Dixit et al who demonstrated that
ghrelin is produced endogenously and secreted by T cells and human peripheral blood
mononuclear cells (PBMCs) and inhibits the secretion of IL-1 β, IL-6, and TNF-α secretion
from LPS-treated human PBMCs 13. These observations are further corroborated by the studies
of Gozalez-Rey and Ceranowicz P et al’s in which they showed that ghrelin had beneficial
effects in rodent models of colitis and pancreatitis 14,15. It has also been shown that pro-
inflammatory cytokine production is decreased after LPS challenge when rodents are pre-
treated with ghrelin in vivo 20. Hence, our results and the limited number of other studies done
in this area demonstrate consistently that ghrelin inhibits pro-inflammatory cytokine
production after an LPS challenge in different types of immune cells.
Of note, the mechanism of ghrelin’s suppressive effect on pro-inflammatory cytokine
production in LPS-stimulated murine macrophages is poorly understood. Hence, we examined
a potential mechanism underlying our findings. The transcription factor, NF-κB at least in part,
controls the production of many pro-inflammatory cytokines, including IL-1β and TNF-α 24.
The promotor region for NFκB has been localized on many pro-inflammatory cytokine genes
and forms the basis of simultaneous release of those cytokines during inflammatory cascade.
21 Consistent with the findings of Li et al’s, we found that ghrelin inhibited the translocation
of LPS-induced NF-κB (p65) into the nucleus in murine macrophages, which might be one
explanation for the suppressive effects of ghrelin on pro-inflammatory cytokine production by
the macrophages after LPS-stimulation. This mechanism warrants further investigation.
The role of ghrelin in mediating the release of anti-inflammatory cytokines such as IL-10 was
also sought. . IL-10 is a pleiotropic cytokine that is produced by a wide variety of cell types,
including CD41 Th0 and Th2 cells, CD81 T cells, B cells, and monocytes/macrophages.30 It
inhibits antigen-driven activity of both Th1 and Th2 subsets, although it facilitates the induction
of Th2 cell types. Our results demonstrate that ghrelin increases IL-10 production, after an LPS
challenge of murine macrophages and increases the time-dependent course of IL-10 secretion
through GHS-R. These findings may explain the anti-inflammatory findings observed by
Gonzalez-Rey at al when they administered ghrelin in a murine model of colitis.14 Our results,
however, show that the augmented response of ghrelin on IL-10 release is not so dramatic. The
potential reason for this could be because Th2 responses play a relatively less active role in
combating inflammatory cascade.
The mechanism by which ghrelin may augments simultaneously the anti-inflammatory
cytokine production and inhibit pro-inflammatory cytokines release is not clear. The
involvement of differential cellular signaling pathways might provide an explanation for this
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biologic phenomenon. In contrast to other pro-inflammatory cytokines, the NFκB promotor
region has not been found on the IL-10 promotor sequence. Some investigators, however have
suggested30 that p38 MAP kinase plays a vital role in IL-10 synthesis after stimulation of
human monocytes with LPS. LPS-induced cell signaling is known to involve activation of
range of MAPK family members, including p38, p42/44 ERK, and JNK MAPK. The p38 MAP
kinase, in particular, has been suggested to regulate IL-10 synthesis through activation of Sp1
transcription factor in human monocytic cells rather through NF-κB pathway.30 In our study,
we found that ghrelin markedly enhanced the activation of p38 MAPK through GHS-R. Hence,
these findings for ghrelin and p38 MAKP may represent a mechanism underlying our ghrelin-
related IL-10 data and explain why ghrelin has opposite effects on TNF-α and IL-1β, which
appear to be related to alterations in NFκB activation. In the future, it would be interesting to
characterize the molecular machinery in thorough detail, by which ghrelin differentially
regulates the activation of NF-κB pathway and p38 MAPK pathway to mediate Th1 and Th2
responses simultaneously.
During the detailed immunologic work over last decade it has become clear that during
pathologic inflammatory conditions, like inflammatory bowel disease and septic shock, the
physiologic balance of these cytokines may be lost in favor of pro-inflammatory cytokine
production and result in acute exacerbation of inflammatory response overall. In the past, the
targeting of individual cytokines has yielded limited efficacy in combating these acute
exacerbations. Ghrelin administration may offer an option for targeting multiple sites of the
inflammatory cascade to control debilitating or even life-threatening inflammatory processes
15-19. Of note, it has already been demonstrated that ghrelin improves survival in models of
rat fecal peritonitis and endotoxic shock and is associated with decreased TNF-α production
17,20.
Obesity itself may represent a pro-inflammatory state.38 Given that obese people have
suppression of ghrelin levels, it is possible that loss of ghrelin-mediated control of the pro-
inflammatory state may be a mechanism underlying the findings in obese individuals. Even
though there are too many missing links between this theory and currently available
experimental evidence, this hypothesis warrants further investigation as we strive to understand
the pathophysiology of obesity. The role of ghrelin in H. pylori induced gastritis, another
inflammatory state, also warrants further investigation.14
In conclusion, we have demonstrated that ghrelin has potent effects on both pro-inflammatory
and anti-inflammatory cytokines in a complementary fashion. The fact that this peptide can
inhibit simultaneously pro-inflammatory pathways while augmenting anti-inflammatory
elements, suggests a potential mechanism through which ghrelin may protect against
pathologic inflammatory conditions. Thus, unlike other interventions, such as individual
targeting of various cytokines by antibodies, ghrelin has the advantage of being able to
modulate inflammation at multiple levels in complementary fashion. The level of response
achieved by ghrelin in suppressing inflammation is similar to other available biologic
interventions.14 Further, study of the role of ghrelin in various inflammatory states and how
it may be modulated is required.
ACKNOWLEDGEMENT
The authors gratefully acknowledge the technical support of Jan D. Rounds, BS.
REFERENCES
1. Murray CD, Kamm MA, Bloom SR, et al. Ghrelin for the gastroenterologist: history and potential.
Gastroenterology 2003;125:1492–502. [PubMed: 14598266]
Waseem et al. Page 7
Surgery. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Wu JT, Kral JG. Ghrelin: integrative neuroendocrine peptide in health and disease. Ann Surg
2004;239:464–74. [PubMed: 15024307]
3. Smith RG, Leonard R, Bailey AR, et al. Growth hormone secretagogue receptor family members and
ligands. Endocrine 2001;14:9–14. [PubMed: 11322507]
4. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in
cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol
2002;159:1029–37. [PubMed: 12486113]
5. Muccioli G, Pons N, Ghe C, et al. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced
lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol
2004;498:27–35. [PubMed: 15363972]
6. Gauna C, Delhanty PJ, Hofland LJ, et al. Ghrelin stimulates, while des-octanoyl ghrelin inhibits,
glucose output by primary hepatocytes. J Clin Endocrinol Metab 2004;9:9.
7. Nanzer AM, Khalaf S, Mozid AM, et al. Ghrelin exerts a proliferative effect on a rat pituitary
somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol
2004;151:233–40. [PubMed: 15296479]
8. Duxbury MS, Waseem T, Ito H, et al. Ghrelin promotes pancreatic adenocarcinoma cellular
proliferation and invasiveness. Biochem Biophys Res Commun 2003;309:464–8. [PubMed:
12951072]
9. Andreis PG, Malendowicz LK, Trejter M, et al. Ghrelin and growth hormone secretagogue receptor
are expressed in the rat adrenal cortex: Evidence that ghrelin stimulates the growth, but not the secretory
activity of adrenal cells. FEBS Lett 2003;536:173–9. [PubMed: 12586359]
10. Kim MS, Yoon CY, Jang PG, et al. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1
adipocytes. Mol Endocrinol 2004;18:2291–301. [PubMed: 15178745]
11. Waseem T, Duxbury MS, Ito H, Rounds J, Gonzalez J, Lautz D, Whang EE, Ashley SW, Robinson
MK. Ghrelin: A Novel Humoral Mediator of Intestinal Adaptation. Gastroenterology 2004;126
(supple 2):A-136.
12. Hattori N, Saito T, Yagyu T, et al. GH, GH receptor, GH secretagogue receptor, and ghrelin expression
in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 2001;86:4284–91. [PubMed:
11549663]
13. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced
proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004;114:57–
66. [PubMed: 15232612]
14. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis.
Gastroenterology 2006;130:1707–20. [PubMed: 16697735]
15. Ceranowicz P, Tomaszewska R, Stachura J, et al. Ghrelin attenuates the development of acute
pancreatitis in rat. J Physiol Pharmacol 2003;54:561–73. [PubMed: 14726611]
16. Otero M, Nogueiras R, Lago F, et al. Chronic inflammation modulates ghrelin levels in humans and
rats. Rheumatology (Oxford) 2004;43:306–10. [PubMed: 14623951]
17. Dembinski A, Warzecha Z, Chang L, et al. Therapeutic effects of ghrelin on endotoxic shock in rats.
Eur J Pharmacol 2003;473:171–6. [PubMed: 12892835]
18. Hataya Y, Akamizu T, Hosoda H, et al. Alterations of plasma ghrelin levels in rats with
lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome.
Endocrinology 2003;144:5365–71. [PubMed: 12960078]
19. Guney Y, Ozel Turkcu U, Hicsonmez A, et al. Ghrelin may reduce radiation-induced mucositis and
anorexia in head-neck cancer. Med Hypotheses 2007;68:538–40. [PubMed: 17030099]
20. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB
activation in human endothelial cells. Circulation 2004;109:2221–6. [PubMed: 15117840]
21. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease.
Annu Rev Med 2000;51:289–98. [PubMed: 10774465]
22. Schilling D, Beissert T, Fenton MJ, et al. Negative regulation of IL-1beta production at the level of
transcription in macrophages stimulated with LPS. Cytokine 2001;16:51–61. [PubMed: 11683585]
23. Wu CH, Chen TL, Chen TG, et al. Nitric oxide modulates pro- and anti-inflammatory cytokines in
lipopolysaccharide-activated macrophages. J Trauma 2003;55:540–5. [PubMed: 14501900]
Waseem et al. Page 8
Surgery. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
24. Makarov SS, Johnston WN, Olsen JC, et al. NF-kappa B as a target for anti-inflammatory gene
therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer
of I kappa B alpha cDNA. Gene Ther 1997;4:846–52. [PubMed: 9338014]
25. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol
Today 1991;12:A49–53. [PubMed: 1648926]
26. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for
activated human B lymphocytes. Proc Natl Acad Sci U S A 1992;89:1890–3. [PubMed: 1371884]
27. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell
1993;75:263–74. [PubMed: 8402911]
28. Yang X, Gartner J, Zhu L, et al. IL-10 gene knockout mice show enhanced Th1-like protective
immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J
Immunol 1999;162:1010–7. [PubMed: 9916727]
29. Song Z, Barve S, Chen T, et al. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated
interleukin-10 production in monocytes. Am J Physiol Gastrointest Liver Physiol 2003;284:G949–
55. [PubMed: 12736147]
30. Ma W, Lim W, Gee K, et al. The p38 mitogen-activated kinase pathway regulates the human
interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-
stimulated human macrophages. J Biol Chem 2001;276:13664–74. [PubMed: 11278848]
31. Foey AD, Parry SL, Williams LM, et al. Regulation of Monocyte IL-10 Synthesis by Endogenous
IL-1 and TNF-{alpha}: Role of the p38 and p42/44 Mitogen-Activated Protein Kinases. J Immunol
1998;160:920–928. [PubMed: 9551930]
32. Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 10 in patients with
inflammatory bowel disease. Gastroenterology 1995;108:1434–44. [PubMed: 7729636]
33. Bondeson J, Browne KA, Brennan FM, et al. Selective Regulation of Cytokine Induction by
Adenoviral Gene Transfer of I{kappa}B{alpha} into Human Macrophages: Lipopolysaccharide-
Induced, But Not Zymosan-Induced, Proinflammatory Cytokines Are Inhibited, But IL-10 Is Nuclear
Factor-{kappa}B Independent. J Immunol 1999;162:2939–2945. [PubMed: 10072544]
34. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell
1993;75:263–74. [PubMed: 8402911]
35. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by
human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med
1991;174:1209–1220. [PubMed: 1940799]
36. Waseem T, Duxbury MS, Ito H, Rocha FG, Lautz D, Whang EE, Ashley SW, Robinson MK. Ghrelin
ameliorates TNF-α induced anti-proliferative and pro-apoptotic effects and promotes intestinal
epithelial restitution. J. Am. Coll. Surg 2004;199(Issue 3 Supple 1):16.
37. De Vriese C, Delporte C. Autocrine proliferative effect of ghrelin on leukemic HL-60 and THP-1
cells. J Endocrinol 2007;192:199–205. [PubMed: 17210757]
38. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953–66. [PubMed: 11744348]
Waseem et al. Page 9
Surgery. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. Ghrelin and GHS-R are expressed constitutively within murine RAW 264.7 macrophages
Fig 1a; Upper panel demonstrates the presence of GHS-R (Cell lysates from rat hypothalamus/
pituitary gland and cerebral cortex were used as positive and negative controls, respectively)
and Lower panel shows the presence of ghrelin at protein level (Ghrelin and cell lysates from
rat stomach were used as positive controls, while cell lysate from rat cerebral cortex served as
a negative controls respectively) in murine macrophage cell line by Western analysis. Fig
1b; Panel (A-C) represents negative controls; Image A is Hoechst staining for nuclei, image
B shows no staining in case of negative controls and in image C, latter images A&B have been
merged. GHS-R is expressed within RAW 264.7 macrophages as shown by immuno-
fluorescence (Panel D-F). Image D is Hoechst staining of the cellular nuclei; image E shows
presence of GHS-R on the cell membrane and in image F, latter images D & E have been
merged. Ghrelin is co-expressed along with GHS-R on cell membrane and also within
cytoplasm (Panel G-I). Image G shows Hoechst staining of nuclei; image H shows the presence
of ghrelin on the cell membrane (white arrow) & within cytoplasm (red arrow) and in image
I latter images G & H have been merged.
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Fig. 2. Exogenous ghrelin pretreatment inhibits LPS-induced release of IL-1β in a dose-dependent
and time-dependent manner through GHS-R in RAW 264.7 macrophages
The measurements are expressed in pg/ml units+/-SD and are derived from three independent
experiments. Fig.2a shows that LPS treatment stimulates the release of IL-1β significantly
above the negative controls (*, p<0.05 vs. no treatment) and ghrelin pretreatment 4 h prior to
LPS treatment (1μg/ml) for 24 h inhibits the release of IL-1β (**, p<0.05 vs. LPS alone). Fig.
2b shows that ghrelin mediated inhibition of LPS-induced IL-1β release is time dependent
being the most pronounced at 24 h after LPS treatment (*p<0.05 vs. LPS treatment alone). Fig
2c shows that GHS-R antagonist D[lys-3]-GHRP-6 abrogates ghrelin-mediated inhibition of
IL-1β release as measured at 0-30h. (*, p<0.05 vs. no treatment ; **, p <0.05 vs. LPS alone;
Ψ, p<0.05 vs. LPS+ Ghrelin).
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Fig. 3. Exogenous ghrelin pretreatment inhibits LPS-induced release of TNF-α in a dose-dependent
and time-dependent manner through GHS-R in RAW 264.7 macrophages
The measurements are expressed in pg/ml units+/-SD and are derived from three independent
experiments. Fig.3a shows that LPS stimulates the release of TNF-α from the RAW 264.7
macrophages (*, p<0.05 vs. no treatment) and ghrelin pretreatment 4 h prior to LPS treatment
(1μg/ml) for 24 h significantly inhibits release of TNF-α (**, p<0.05 vs. LPS alone). Fig.3b
shows that ghrelin mediated inhibition of LPS-induced TNF-α release is time-dependent being
most pronounced at 6 hours after LPS treatment (*p<0.05 vs. LPS treatment). Fig 3c
demonstrates that GHS-R antagonist D[lys-3]-GHRP-6 significantly but not completely
abolishes ghrelin-mediated inhibition of TNF-α release as measured after 24 h (*, p <0.05 vs.
no treatment; **, p<0.05 vs. LPS alone; Ψ, p < 0.05 vs. LPS+ghrelin).
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Fig. 4. Exogenous ghrelin inhibits LPS-induced translocation of p65 subunit of NFκB into the
nuclear compartment in murine RAW 264.7 macrophages
Fig. 4a, Western analysis; RAW 264.7 macrophages were pre-treated with various agents
including ghrelin (0-100nM), D[lys-3]-GHRP-6 (1μM) and a selective NFκB inhibitor (6-
Amino-4-(4-phenoxyphenylethylamino)quinazoline) (1μM) 60 minutes prior to the LPS
(1μg/ml) treatment, nuclear extracts were prepared as described in the Materials and
Methods section and were subjected to Western analysis for assessment of nuclear content of
p65 NFκB; lane a, no treatment; lane b, ghrelin; lane c, LPS (1μg/ml); lane d, ghrelin (1nM)
+ LPS (1μg/ml); lane e, ghrelin (10nM) + LPS (1μg/ml); lane f, ghrelin (100nM) + LPS (1μg/
ml); lane g, D [lys-3]-GHRP-6 (1μM) +ghrelin (10nM) + LPS (1μg/ml); lane h, NFκB inhibitor
+ ghrelin (10nM) + LPS (1μg/ml). Fig. 4b, Immuno-florescent staining for p65 subunit of
NFκB; RAW 264.7 cells were pre-treated with various substances 60 min prior to stimulation
with LPS for 15 min; cells were stained with DAPI and p65 subunit of NFκB antibody; A, light
microscopic image of the cells; B, no treatment; C, LPS treatment- the p65 subunit translocates
to nuclear region; D, LPS(1μg/ml)+ ghrelin 10nM; E, LPS(1μg/ml)+D[lys-3]-GHRP-6 pre-
treatment + ghrelin; F, LPS(1μg/ml)+ D[lys-3]-GHRP-6 pre-treatment + ghrelin + NFκB
inhibitor.
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Fig. 5. Exogenous ghrelin pretreatment augments LPS-induced release of IL-10 in a dose dependent
and time-dependent manner through GHS-R in RAW 264.7 macrophages
The measurements are expressed in pg/ml units+/-SD and are derived from three independent
experiments. Fig.5a shows that LPS provides effective stimulation for the release of IL-10 (*,
p<0.05 vs. no treatment) and ghrelin pretreatment 4 h prior to LPS treatment (1μg/ml) for 24
h significantly stimulates release of IL-10 (**, p<0.05 vs. LPS alone). Fig.5b shows that ghrelin
mediated accentuation of LPS-induced IL-10 release is time dependent being most pronounced
at 24 h following LPS treatment (*, p<0.05 vs. LPS treatment alone). Fig 5c indicates that
GHS-R antagonist D[lys-3]-GHRP-6 abrogates ghrelin-mediated augmentation of IL-10
release (*, p <0.05 vs. no treatment; **, p <0.05 vs. LPS alone; Ψ p<0.05 vs. LPS+Ghrelin).
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Fig. 6. Exogenous ghrelin promotes enhanced activation of p38 MAPK in LPS-stimulated murine
RAW264.7 cells
Western analysis; RAW 264.7 cells were pre-treated with peptides and chemicals for 1h before
stimulation with LPS, cell lysates were harvested 15 min after LPS stimulation and were
subjected to Western analysis for p-p38 MAPK, which was subsequently probed with p38
MAPK antibody to measure the total content of p38 MAPK; lane a, no treatment; lane b, LPS
(1μg/ml); lane c, ghrelin (100nM) + LPS (1μg/ml); lane d, SB202190 (1μg/ml) + ghrelin
(100nM) + LPS (1μg/ml); lane e; D[lys-3]-GHRP-6 (1μg/ml) + ghrelin (100nM) + LPS (1μg/
ml).
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